Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches.

Paul S.

Bioessays. 2008 Nov;30(11-12):1172-84. doi: 10.1002/bies.20852. Review.

PMID:
18937370
2.

The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.

Ross CA, Pickart CM.

Trends Cell Biol. 2004 Dec;14(12):703-11. Review.

PMID:
15564047
3.
4.

Proteasome-independent functions of ubiquitin in endocytosis and signaling.

Mukhopadhyay D, Riezman H.

Science. 2007 Jan 12;315(5809):201-5. Review.

PMID:
17218518
5.

The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype.

van Tijn P, Hol EM, van Leeuwen FW, Fischer DF.

Prog Neurobiol. 2008 Jun;85(2):176-93. doi: 10.1016/j.pneurobio.2008.03.001. Epub 2008 Mar 18. Review.

PMID:
18448229
6.
7.

Ubiquitin proteasome system as a pharmacological target in neurodegeneration.

Hol EM, Fischer DF, Ovaa H, Scheper W.

Expert Rev Neurother. 2006 Sep;6(9):1337-47. Review.

PMID:
17009921
8.

Quality control of the proteins associated with neurodegenerative diseases.

Gao X, Hu H.

Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):612-8. Review.

9.

Narrative review: protein degradation and human diseases: the ubiquitin connection.

Reinstein E, Ciechanover A.

Ann Intern Med. 2006 Nov 7;145(9):676-84. Review.

PMID:
17088581
10.
11.

Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.

de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM.

Prog Neurobiol. 2004 Dec;74(5):249-70. Review.

PMID:
15582222
12.

Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.

Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC.

Curr Top Dev Biol. 2006;76:89-101. Review.

PMID:
17118264
13.

Fluorescent reporters for the ubiquitin-proteasome system.

Salomons FA, Verhoef LG, Dantuma NP.

Essays Biochem. 2005;41:113-28. Review.

PMID:
16250901
14.

Monitoring the ubiquitin/proteasome system in conformational diseases.

Lindsten K, Dantuma NP.

Ageing Res Rev. 2003 Oct;2(4):433-49. Review.

PMID:
14522245
15.

The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?

Dennissen FJ, Kholod N, van Leeuwen FW.

Prog Neurobiol. 2012 Feb;96(2):190-207. doi: 10.1016/j.pneurobio.2012.01.003. Epub 2012 Jan 16. Review.

PMID:
22270043
16.

Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies.

Upadhya SC, Hegde AN.

Curr Pharm Des. 2005;11(29):3807-28. Review.

PMID:
16305513
17.
18.

Removing protein aggregates: the role of proteolysis in neurodegeneration.

Nijholt DA, De Kimpe L, Elfrink HL, Hoozemans JJ, Scheper W.

Curr Med Chem. 2011;18(16):2459-76. Review.

PMID:
21568912
19.

The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders.

Iacovelli L, Fulceri F, De Blasi A, Nicoletti F, Ruggieri S, Fornai F.

Exp Neurol. 2006 Sep;201(1):24-31. Epub 2006 May 5. Review.

PMID:
16678160
20.

Alternative UPS drug targets upstream the 26S proteasome.

Hjerpe R, Rodríguez MS.

Int J Biochem Cell Biol. 2008;40(6-7):1126-40. doi: 10.1016/j.biocel.2007.11.021. Epub 2007 Dec 8. Review.

PMID:
18203645

Supplemental Content

Support Center